De Novo high-volume metastatic prostate cancer with primary resistance to standard systemic therapy and exceptional response to PSMA-Lu177: A case report.
증례보고
1/5 보강
Prostate specific membrane antigen (PSMA) Lutetium-177 (Lu-177) therapy is a relatively new theranostic treatment using a targeted radioligand therapy in the treatment of metastatic prostate cancer.
APA
Rafizadeh D, Kaakour D, et al. (2026). De Novo high-volume metastatic prostate cancer with primary resistance to standard systemic therapy and exceptional response to PSMA-Lu177: A case report.. International cancer conference journal, 15(1), 154-159. https://doi.org/10.1007/s13691-025-00834-2
MLA
Rafizadeh D, et al.. "De Novo high-volume metastatic prostate cancer with primary resistance to standard systemic therapy and exceptional response to PSMA-Lu177: A case report.." International cancer conference journal, vol. 15, no. 1, 2026, pp. 154-159.
PMID
41589251 ↗
Abstract 한글 요약
Prostate specific membrane antigen (PSMA) Lutetium-177 (Lu-177) therapy is a relatively new theranostic treatment using a targeted radioligand therapy in the treatment of metastatic prostate cancer. PSMA-Lu177 has been approved by the FDA for treatment of prostate cancer in the metastatic castrate resistant setting. Here, we present the case of a 90-year-old man with metastatic castrate resistant prostate cancer (mCRPC) and primary resistance to androgen deprivation, second-generation androgen receptor inhibitors, and docetaxel chemotherapy. Despite the lack of response to prior lines of therapy, the patient demonstrated a rapid response to PSMA-Lu177 therapy with a substantial drop in PSA level, starting from the first cycle.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- PrP-Neutralizing Antibody Confers an Additive Benefit in Combination with 5-Fluorouracil in KRAS-Mutant Colorectal Cancer Models, Associated with Reduced RAS-GTP and AKT/ERK Phosphorylation.
- Dihydrocapsaicin Secreted by RYK Silenced Bone Marrow-Derived Mesenchymal Stem Cells Triggers Apoptosis of Gastric Cancer Cells.
- Prostatic malakoplakia mimicking prostate cancer in an elderly male with prostatitis: A rare but important differential.
- Patient-reported outcomes in TALAPRO-2 trial: addressing data integrity and comparative clinical benefit in mCRPC.
- Association between biochemical and histopathological parameters in the clinical assessment of prostate tumors in a resource-limited setting in northern Cameroon.
- PROSTest, a Multigene Liquid Biopsy Signature, Effectively Stratifies Patients With High PSA for Prostate Biopsy.